Pfizer and BioNTech approved to start phase 2/3 trial of Covid-19 vaccine

The German regulatory authority, the Paul-Ehrlich-Institut, has approved a phase 2/3 clinical trial in Germany of a Covid-19 vaccine candidate being developed by US pharmaceutical company Pfizer and German biotechnology company BioNTech. Pročitaj više